

This communication should be viewed by:

Administrative Staff Clinical staff

Pharmaceutical Policies Updates Effective September 1, 2023

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at **mvphealthcare.com** and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- New Denotes a new policy
- **Updated** Updated policies have content changes that may affect coverage criteria for services and/or drugs
- Reviewed/No Changes Policies that have been reviewed but have no content change
- Archived Denotes a policy that is no longer active

The following policies are effective September 1, 2023 and will be available for viewing on or before August 1, 2023. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Cystic Fibrosis (Select Agents for Inhalation)	Reviewed/No Changes
Xolair	Reviewed/No Changes
Drug Utilization Review and Monitoring Program	Reviewed/No Changes
Cystic Fibrosis (Select Oral Agents)	Updated
Select injectable for Asthma	Updated
Idiopathic Pulmonary Fibrosis	Updated
Certolizumab	Updated
Preventative Services- Medication	Updated
Quantity Limits for Prescription Drugs	Updated
Specialty Drug Procurement Exception Effective July 1, 2023	Archived
Pharmacy Programs Management Effective July 1, 2023	Updated
C. difficile Drug Therapy Effective August 1, 2023	New

It's Time to Recertify Your Patients!*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit **mvphealthcare.com/recertification.**

*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

